Boehringer Ingelheim’s LUME-Lung 1 Phase III clinical trial of novel investigational compound nintedanib has provided a significant and clinically relevant overall survival benefit for advanced non-small cell lung cancer (NSCLC) patients with adenocarcinoma histology.
Nintedanib is an investigational compound that is not yet approved or had its safety and efficacy fully established.
Go deeper with GlobalData
It is an oral triple angiokinase inhibitor that targets three receptors crucially involved in angiogenesis and tumour growth. Angiokinase is one of the key processes leading to invasion and metastasis of solid tumours
LUME-Lung 1 showed nintedanib, plus chemotherapy drug docetaxel, provided a statistically significant increase in median overall survival from 10.3 months in the placebo arm to 12.6 months in the nintedanib arm, Boehringer Ingelheim reported.
In addition, the data demonstrated that the earlier adenocarcinoma patients failed first line chemotherapy, the bigger the benefit nintedanib provided. Adenocarcinoma is a cancer of an epithelium that originates in glandular tissue.
See Also:
Compared with the overall adenocarcinoma patient population, patients with advanced adenocarcinoma who progressed within nine months after the start of their first-line treatment achieved a larger median overall survival benefit of three months.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataHerlev University Hospital Copenhagen Department of Oncology Dr Anders Mellemgaard said Adenocarcinoma is the most common form of non-small cell lung cancer and the majority of patients with an advanced stage of the disease will ultimately progress after initial therapy, therefore effective second-line treatments are vital.
"Recent treatment advances for this sizeable patient population have been limited, but we have reached an important milestone with nintedanib," Dr Anders said.
"LUME-Lung 1 showed that nintedanib when added to chemotherapy was effective in extending overall survival by 2.3 months for advanced non-small cell lung cancer patients with adenocarcinoma histology and could become an important second-line option for these patients."
Image: Micrograph of an adenocarcinoma showing mucin containing vacuoles. Photo: courtesy of Nephron.
